BioNTech Slips To Loss In Q1
(RTTNews) - Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Monday a net loss of 315.1 million euros or 1.31 euros per share for the first quarter, compared to net profit of 502.2 million euros or 2.05 euros per share in the prior-year quarter.
Total revenues for the quarter plummeted to 187.6 million euros from 1.28 billion euros in the same quarter last year, mainly due to sharply lower demand for COVID-19 vaccines.
Looking ahead to fiscal 2024, the company continues to project group revenues in the range of 2.5 billion to 3.1 billion euros.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
read more
FDA Approves Updated Pfizer, Moderna Covid Vaccines Against Current Variants
The U.S. Food and Drug Administration approved and granted emergency use authorization or EUA for updated Covid vaccines from Pfizer Inc. and ModernaTX Inc. for use against currently circulating variants. The approval for the updated mRNA COVID-19 vaccines (2024-2025 formula) comes as the Covid cases are surging in the United States.
RTTNews
|
88 일 전
Pfizer, BioNTech Announce Top-line Results In Phase 3 Trial Of MRNA-based Combination Vaccine
Drug giant Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Friday top-line results from their Phase 3 clinical trial to evaluate the companies' combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age.
RTTNews
|
94 일 전
BioNTech And CEPI Expand Strategic Partnership To Boost African Vaccine Ecosystem
BioNTech SE (BNTX) and the Coalition for Epidemic Preparedness Innovations or CEPI, announced Wednesday they are expanding their strategic partnership to contribute to building a sustainable and resilient end-to-end African vaccine ecosystem.
RTTNews
|
174 일 전
BioNTech Q4 Net Profit Plummets
Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) announced Wednesday a profit for the fourth quarter that plummeted from last year, reflecting sharply lower global delivery of its COVID-19 vaccine. The company also initiated its group revenue guidance for the full-year 2024.
RTTNews
|
244 일 전
BioNTech To Initiate Phase 1/2 Clinical Trial Of MRNA-based Mpox Vaccine Program BNT166
BioNTech SE (BNTX) and the Coalition for Epidemic Preparedness Innovations (CEPI) announced Monday a strategic partnership to advance mRNA-based vaccine candidates with the development of BNT166 for the prevention of mpox (formerly monkeypox)
RTTNews
|
428 일 전
FDA Authorizes Changes To Simplify Use Of Moderna, Pfizer Bivalent COVID-19 Vaccines
The U.S. Food and Drug Administration said it has amended the emergency use authorizations or EUAs of COVID-19 bivalent mRNA vaccines of ModernaTX Inc. and Pfizer-BioNTech to simplify the vaccination schedule for most individuals. With the changes, the current bivalent vaccines, for original and omicron BA.4/BA.5 strains, can be used for all doses administered to individuals 6 months of age and...
RTTNews
|
580 일 전
FDA Authorizes Bivalent Pfizer Covid Vaccine As Booster Dose For Select Children Under 5
The U.S. Food and Drug Administration has authorized bivalent Pfizer-BioNTech covid-19 vaccine as booster dose for certain children 6 months through 4 years of age. In a statement, the health regulator said it has amended the emergency use authorization or EUA of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent. According to the agency, children 6 months through 4 years of age who completed ...
RTTNews
|
615 일 전
Pfizer Seeks FDA Approval For Bivalent COVID-19 Vaccine In Kids Under 5
Vaccine partners Pfizer Inc. and BioNTech SE are seeking emergency use authorization or EUA from the U.S. Food and Drug Administration to offer their bivalent COVID-19 vaccine to children 6 months through 4 years of age. If authorized, the vaccine would be part of a primary series for children in this age group.
RTTNews
|
714 일 전
